Antiviral strategies against Chikungunya virus

Methods in Molecular Biology

Volumn 1426, Issue , 2016, Pages 243-253

  Abdelnabi, Rana ^a   Neyts, Johan ^a   Delang, Leen ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antivirals; Arbidol; Chikungunya virus; Chloroquine; Favipiravir; Immune modulators; Ribavirin

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 3; ALPHA INTERFERON; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; ANTIVIRUS AGENT; APLYSIATOXIN; ARBIDOL; AZAURIDINE; CHLOROQUINE; CHRYSIN; DITERPENOID; EPIGALLOCATECHIN GALLATE; FAVIPIRAVIR; HARRINGTONINE; HEAT SHOCK PROTEIN 90 INHIBITOR; HOMOHARRINGTONINE; MYCOPHENOLIC ACID; PHENOTHIAZINE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN KINASE C ACTIVATOR; RETINOIC ACID INDUCIBLE PROTEIN I; RIBAVIRIN; TRIGOCHERRIERIN A; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; PROTEIN KINASE INHIBITOR; VIRAL PROTEIN;

CHIKUNGUNYA; CHIKUNGUNYA VIRUS; HUMAN; HUMAN CELL; RNA INTERFERENCE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; PROTEIN SYNTHESIS; VIRUS ENTRY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CLINICAL TRIALS AS TOPIC; HUMANS; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; VIRAL PROTEINS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84988842337     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3618-2_22     Document Type: Chapter

References (48)

1. Simon F, Javelle E, Oliver M et al (2011) Chikungunya virus infection. Curr Infect Dis Rep 13:218-228
2. Cavrini F, Gaibani P, Pierro AM et al (2009) Chikungunya: an emerging and spreading arthropod-borne viral disease. J Infect Dev Ctries 3:744-752
3. Kucharz EJ, Cebula-Byrska I (2012) Chikungunya fever. Eur J Intern Med 23:325-329
4. Ali Ou Alla S, Combe B (2011) Arthritis after infection with Chikungunya virus. Best Pract Res Clin Rheumatol 25:337-346
5. Teissier E, Zandomeneghi G, Loquet A et al (2011) Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 6(1), e15874
6. Kaur P, Chu JJ (2013) Chikungunya virus: an update on antiviral development and challenges. Drug Discov Today 18:969-983
7. Brighton SW (1984) Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open pilot study. S Afr Med J 66: 217-218
8. De Lamballerie X, Boisson V, Reynier J-C et al (2008) On Chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 8:837-839
9. Blaising J, Polyak SJ, Pécheur EI (2014) Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 107:84-94
10. Delogu I, Pastorino B, Baronti C et al (2011) In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 90: 99-107
11. Di Mola A, Peduto A, La Gatta A et al (2014) Structure-activity relationship study of arbidol derivatives as inhibitors of Chikungunya virus replication. Bioorg Med Chem 22: 6014-6025
12. Pohjala L, Utt A, Varjak M et al (2011) Inhibitors of alphavirus entry and replication identifi ed with a stable Chikungunya replicon cell line and virus-based assays. PLoS One 6, e28923
13. Weber C, Sliva K, von Rhein C et al (2015) The green tea catechin, epigallocatechin gallate inhibits Chikungunya virus infection. Antiviral Res 113:1-3
14. Dash PK, Tiwari M, Santhosh SR et al (2008) RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun 376: 718-722
15. Parashar D, Paingankar MS, Kumar S et al (2013) Administration of E2 and NS1 siRNAs inhibit Chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Negl Trop Dis 7(9), e2405
16. Lam S, Chen KC, Ng MML, Chu JJ (2012) Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced Chikungunya virus replication. PLoS One 7(10), e46396
17. Kaur P, Thiruchelvan M, Lee RCH et al (2013) Inhibition of Chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother 57:155-167
18. Turner TL, Kopp BT, Paul G et al (2014) Respiratory syncytial virus: current and emerging treatment options. Clin Outcomes Res 6:217-225
19. Pawlotsky JM (2014) New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146:1176-1192
20. Briolant S, Garin D, Scaramozzino N et al (2004) In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-α and ribavirin combination. Antiviral Res 61:111-117
21. Khan M, Dhanwani R, Patro IK et al (2011) Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res 89:1-8
22. Leyssen P, De Clercq E, Neyts J (2006) The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol 69:1461-1467
23. Paeshuyse J, Dallmeier K, Neyts J (2011) Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 1:590-598
24. Rada B, Dragún M (1977) Antiviral action and selectivity of 6-azauridine. Ann N Y Acad Sci 284:410-417
25. Furuta Y, Gowen BB, Takahashi K et al (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446-454
26. Delang L, Segura Guerrero N, Tas A et al (2014) Mutations in the Chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69:2770-2784
27. Solignat M, Gay B, Higgs S et al (2009) Replication cycle of Chikungunya: a reemerging arbovirus. Virology 393:183-197
28. Fros JJ, van der Maten E, Vlak JM, Pijlman GP (2013) The C-terminal domain of Chikungunya virus nsP2 independently governs viral RNA replication, cytopathicity, and inhibition of interferon signaling. J Virol 87:10394-10400
29. Lucas-Hourani M, Lupan A, Despres P et al (2012) A phenotypic assay to identify Chikungunya virus inhibitors targeting the nonstructural protein nsP2. J Biomol Screen 18(2):172-179
30. Bassetto M, De Burghgraeve T, Delang L et al (2013) Computer-aided identifi cation, design and synthesis of a novel series of compounds with selective antiviral activity against Chikungunya virus. Antiviral Res 98:12-18
31. Jadav SS, Sinha BN, Hilgenfeld R et al (2015) Thiazolidone derivatives as inhibitors of Chikungunya virus. Eur J Med Chem 89: 172-178
32. Ozden S, Lucas-Hourani M, Ceccaldi P-E et al (2008) Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein. J Biol Chem 283: 21899-21908
33. Bourjot M, Delang L, Nguyen VH et al (2012) Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of Chikungunya virus replication. J Nat Prod 75:2183-2187
34. McKernan LN, Momjian D, Kulkosky J (2012) Protein kinase C: one pathway towards the eradication of latent HIV-1 reservoirs. Adv Virol 2012:805347
35. Cruz DJM, Bonotto RM, Gomes RGB et al (2013) Identifi cation of novel compounds inhibiting Chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library. PLoS Negl Trop Dis 7(10), e2471
36. Rathore APS, Haystead T, Das PK et al (2014) Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and infl ammation in vivo. Antiviral Res 103:7-16
37. Schwartz O, Albert ML (2010) Biology and pathogenesis of Chikungunya virus. Nat Rev Microbiol 8:491-500
38. Bordi L, Meschi S, Selleri M et al (2011) Chikungunya virus isolates with/without A226V mutation show different sensitivity to IFN-alpha, but similar replication kinetics in non human primate cells. New Microbiol 34:87-91
39. Bréhin A-C, Casadémont I, Frenkiel M-P et al (2009) The large form of human 2′,5′-Oligoadenylate Synthetase (OAS3) exerts antiviral effect against Chikungunya virus. Virology 384:216-222
40. Gad HH, Paulous S, Belarbi E et al (2012) The E2-E166K substitution restores Chikungunya virus growth in OAS3 expressing cells by acting on viral entry. Virology 434:27-37
41. Li Y-G, Siripanyaphinyo U, Tumkosit U et al (2012) Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells. Virol J 9:114
42. Hornung V, Ellegast J, Kim S et al (2006) 5′-Triphosphate RNA is the ligand for RIGI. Science 314:994-997
43. Pichlmair A, Schulz O, Tan CP et al (2006) RIG-I-mediated antiviral responses to singlestranded RNA bearing 5′-phosphates. Science 314:997-1001
44. Olagnier D, Scholte FEM, Chiang C et al (2014) Inhibition of dengue and Chikungunya virus infection by RIG-I-mediated type I IFNindependent stimulation of the innate antiviral response. J Virol 88:4180-4194
45. Bourjot M, Leyssen P, Neyts J et al (2014) Trigocherrierin a, a potent inhibitor of Chikungunya virus replication. Molecules 19: 3617-3627
46. Gupta DK, Kaur P, Leong ST et al (2014) Anti-Chikungunya viral activities of aplysiatoxinrelated compounds from the marine cyanobacterium Trichodesmium erythraeum. Mar Drugs 12:115-127
47. Hawman DW, Stoermer KA, Montgomery SA et al (2013) Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol 87:13878-13888
48. Morrison TE, Oko L, Montgomery SA et al (2011) A mouse model of Chikungunya virusinduced musculoskeletal infl ammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol 178:32-40